OncoMatch/Clinical Trials/NCT06731413
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
Is NCT06731413 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Reduced Dose of Chemotherapy and Immunotherapy for non-small cell lung cancer.
Treatment: Reduced Dose of Chemotherapy and Immunotherapy — Evaluate frequency of adverse events that lead to chemotherapy discontinuation in vulnerable older adults with recurrent/metastatic PD-L1 TPS\<50% NSCLC patients who receive reduced dose chemotherapy in combination with immunotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) tumor proportion score (TPS) of less than 50% (<50%)
PD-L1 tumor proportion score (TPS) of less than 50%
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Lab requirements
Blood counts
ANC ≥ 1,000/μL; Platelets ≥ 75,000/μL; Hemoglobin (Hgb) ≥ 8.0 g/dL (transfusion permitted)
Kidney function
Creatinine clearance of <30 mL/min [excluded]
Liver function
Total bilirubin ≤ 2 x institutional upper limit of normal (ULN); AST/ALT ≤ 5.0 × institutional ULN
ANC ≥ 1,000/μL; Platelets ≥ 75,000/μL; Hemoglobin (Hgb) ≥ 8.0 g/dL (transfusion permitted); Total bilirubin ≤ 2 x institutional upper limit of normal (ULN); AST/ALT ≤ 5.0 × institutional ULN; Creatinine clearance of <30 mL/min [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Virginia Commonwealth University · Richmond, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06731413 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 tumor proportion score (TPS) of less than 50% is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIB or IIIC or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify